cyrilzakka/clinical-trials huggingface dataset:
Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol

Confirm central blood pressure reduction effect of Fimasartan, Valsartan and Atenolol and compare correlation with the measured peripheral (central blood pressure, pulse wave velocity, and flow-mediated dilation) and cerebral blood flow factors (transcranial doppler findings, cerebral blood flow volume) in acute ischemic stroke patients with hypertension.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 30 years old
* Acute ischemic stroke patient who has corresponding DWI(diffusion- weighted imaging) lesion correlated with symptom
* after 7days, but within 28days from stroke onset
* Diagnosed with Hypertension
* hypertensive patients who taking anti-hypertensive drugs or SBP≥140mmHg
* Informed consent

Exclusion Criteria:

* Patients with hemorrhagic Stroke
* Patients with severe Stroke - over NIHss(National Institutes of Health stroke scale) 16
* Uncontrolled hypertension (SBP ≥200mmHg)
* Patients with history of allergic reaction to any angiotensin II antagonist
* Liver disease(more than double to normal level, SGOT(serum glutamic-oxaloacetic transaminase ), SGPT(serum glutamic-pyruvic transaminase ), total bilirubin)
* Renal disease(serum creatinine ≥2.0mg/dl)
* Anemia(Hb \< 8mg/dl)
* Thrombocytopenia( \< 10\^3/ml)
* Patients with secondary hypertension
* Childbearing and breast-feeding women
* Otherwise inappropriate patients depending on the investigator's decision
Health Management Model Construction and Effect Evaluation of Hypertension Patients Based on Disease-related Health Literacy

Huzhou City, Zhejiang Province was chosen as the research site, and a general hospital was randomly selected. The "Chinese version of hypertension health literacy scale" of the tutor of this research group was used to evaluate the health literacy level of inpatients with hypertension in the Department of Cardiology, and the patients with critical and lack of health literacy were selected as the research objects. In the control group, routine health management was carried out. On the basis of the control group, the intervention group used health education tools combined with health literacy intervention to implement interactive health management for 12 months. The results of the intervention measures were compared to evaluate the effects of the intervention measures on improving the health literacy level, Hypertension Self-care ability, quality of life and reducing systolic and diastolic blood pressure, body mass index, waist circumference, physiological and biochemical indicators of the patients, so as to provide theoretical basis and practical reference for the further development of prevention and treatment strategies of hypertension patients.

First, the Chinese version of hypertension health literacy scale was used to evaluate the health literacy of inpatients in a hospital, and then the critical and lack of health literacy patients were selected as the research objects.

Then, taking a place in Huzhou City of Zhejiang Province as the research site, a general hospital was randomly selected. According to the ratio of male to female = 1:1, the hypertension patients who meet the inclusion criteria were screened until the intervention group and the control group reached the required sample size. Patients were randomly assigned to the intervention group and the control group.

After the patients signed the informed consent, the patients were intervened. Finally, data collection and statistical processing are carried out

Eligibility Criteria:
Inclusion Criteria：

* Age ≥ 16 years old and has lived in Huzhou for nearly half a year;
* The Chinese version of the hypertension health literacy scale was used to evaluate the health literacy of those with a total score of less than 32 + the critical group;
* In line with the diagnostic criteria for essential hypertension set out in China's hypertension prevention and control guidelines in 2018, systolic blood pressure ≥ 140mmHg, and / or diastolic blood pressure ≥ 90mmHg;
* In the last half year, the living condition is stable, and there is no major stress event (such as the death of relatives, etc.);
* Volunteer to participate in the study, and sign the informed consent of research willingness.

Inclusion Criteria：

* All kinds of secondary hypertension patients;
* Major stress events occurred during the study period;
* Have serious mental disorder or serious cognitive function defect;
* Patients with severe acute and chronic physical diseases；
* Cardiovascular risk factors: low risk or high risk.
Effects Of Losartan On Myocardial Structure In Diabetic Hypertensive Patients With Left Ventricular

The anthypertensive treatment with Losartan may have benefits beyond blood pressure reduction on myocardial structure and function in hypertensive diabetic patients. We will evaluate the effect of losartan treatment on structural characteristics of myocardium in hypertensive diabetic patients:

1. left ventricular mass, intraventricular septal thickness, fractional shortening.
2. myocardial qualitative alteration and heterogeneity of myocardial tissue that describes myocardial texture and echodensity, related to collagen deposition; myocardial qualitative alteration will be evaluate by ultrasonic myocardial integrated backscatter signals (IBS) both as peak end diastolic signal intensity and as cardiac cyclic variation
3. alteration of diastolic function as studied by Doppler flow velocities across the mitral valve (Pulse Wave Doppler) and pulse wave Tissue Doppler Imaging parameters
4. aortic strain and distensibility (that is in relation with LVH)
5. epicardial adipose tissue measurement (this parameter is related to the visceral fat and may be an easy method to indicate patients with high cardiovascular risk).


Eligibility Criteria:
Inclusion Criteria:

* Gender: 50% Male and 50 % female
* Age: 40-80 years
* Race: caucasian
* Well controlled type II Diabetes : fasting glicemia \< 126 mg/dl in two different determinantion or any non fasting glicemia \> 200 mg/dl; HbA1c \< 7%
* Mild to moderate hypertension (BP\>130/80mmHg; \<160/100mmHg)
* Left ventricular hypertrophy (LVMI \> 131/110 g/m2 in males/females respectively)

Exclusion Criteria:

* other anthypertensive treatment after wash out period of 2 weeks
* abnormal heart rest function (EF \< 55%).
* valvular heart disease
* congenital heart disease
* heart failure or prior myocardial infarction
* renal disease
* liver disease
* connective tissue disease
* pregnancy or lactation
* sensitivity to the study drugs
* contraindication from an approved label
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement

This is a phase 2 study to investigate the efficacy and safety of Pemigatinib in treating patients with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 rearrangement who have failed at least 1 previous therapy


Eligibility Criteria:
Inclusion Criteria:

1. Men and women, aged 18 or older.
2. Histologically or cytologically confirmed cholangiocarcinoma which was considered to be advanced/metastatic or surgically unresectable by the investigator through image examination.
3. Radiographically measurable disease per RECIST v 1.1
4. Documentation of FGFR2 rearrangement.
5. Documented disease progression after at least 1 line of prior systemic therapy.
6. ECOG performance status of 0\~1.
7. Life expectancy ≥12 weeks.

Exclusion Criteria:

1. Prior receipt of a selective FGFR inhibitor.
2. History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of softy tissues ( exception: skin, kidney, tendons or vessels due to injury, disease, and aging, in the absence of systemic mineral imbalance).
3. Currently evidence of clinically significant corneal or retinal disorder confirmed by ophthalmologic examination.
4. Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half-lives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed.
UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis

Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis. However, in a portion of cases adalimumab does not induce reduction of psoriasis area and severity index (PASI) of 75% or greater, now being considered as gold standard for treatment efficacy. In this study we aim to determine in a randomized half-side comparison whether additional narrowband UVB-311nm phototherapy accelerates and improves the clearance of psoriatic lesions in adalimumab-treated patients after initial slow response.

Patients with moderate to severe psoriasis who have received treatment with adalimumab (loading dose of 80 mg and thereafter 40 mg s.c. biweekly) for at least 6 weeks without a PASI reduction of 75% or greater qualify for the study. Adalimumab is continued and UVB-311nm phototherapy is added at 6 weeks or thereafter one a randomized body half (left or right; head exempt) 3 x per week until complete response (defined as reduction in PASI to \< 3) for a maximum of another 6 weeks (until week 12). PASI score, visual analogue score (VAS) patient score for therapeutic response, and VAS patient score for severity of skin lesions is assessed weekly; and at follow-up visits at month 3, 6, and 12. Paired Wilcoxon testing for differences in PASI and patient VAS scores is done; Fischer exact test is applied to determine differences in complete remission, PASI reduction \> 90%, \> 75% and/or 50% between body sites.

Eligibility Criteria:
Inclusion Criteria:

* Psoriasis patients with PASI reduction of less than 75% after at least 6 weeks of treatment with adalimumab.

Exclusion Criteria:

* Pregnancy or lactation
* History of skin cancer
* Presence of or history of malignant skin tumors
* Dysplastic melanocytic nevus syndrome
* Antinuclear antibodies (ds-DNA, Ro/SSA, La/SSB)
* Autoimmune disorders such as Lupus erythematosus or Dermatomyositis
* Photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma pigmentosum, basal cell nevus syndrome, and others
* General poor health status
Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules

To investigate the Racecadotril pharmacokinetic linearity after single oral administration of 10, 30 and 60 mg as a suspension.

To evaluate the comparative bioavailability of the new Racecadotril formulation (suspension) versus the reference sachet formulation (granules)

This is a single center, open-label, single oral dose, 4-period cross-over study to assess the bioequivalence of a new formulation (suspension) in healthy male volunteers.

Eligibility Criteria:
Inclusion Criteria:

* Healthy male,
* 18 to 45 years old,
* be certified as normal by a comprehensive clinical assessment (detailed medical history and a complete physical examination), arterial blood pressure (BP), heart rate (HR), an ECG and laboratory investigations (haematological, blood chemistry tests, urinalysis), the results of which are within the normal range and/ or judged by the investigator as clinically acceptable for healthy subjects,
* Body Mass Index (BMI) between 18 and 28 kg/m2.

Exclusion Criteria:

* History of cardiovascular, pulmonary gastro-intestinal, hepatic, renal, metabolic, haematological, neurological, psychiatric, systemic, or infectious disease.
* Any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
* Subject has used any drug including OTC products two weeks before the scheduled administration of study drug, except paracetamol (maximum 1g/day).
Airway Inflammation in Congenital Diaphragmatic Hernia Patients

We propose to examine Congenital Diaphragmatic Hernia (CDH) patients for evidence of airway inflammation as a first step to characterize the reported bronchodilator responsiveness. Airway biopsy studies are invasive and thus we propose to perform induced sputum studies to document the amount and type of inflammation present. Another ancillary non-invasive measure of airway inflammation that we will use is exhaled nitric oxide (NO). The primary objective of this study is to determine if CDH patients have any evidence of airway inflammation. The hypothesis of this study is that children with CDH do not have evidence of airway inflammation associated with bronchodilator responsiveness. Based on this information, treatment for CDH patients will hopefully be more accurate and appropriate for their specific needs.


Eligibility Criteria:
Inclusion Criteria:

* 6 - 18 years of age at enrolment
* Clinically stable at enrolment
* Attending follow-up in the CDH Clinic at SickKids

Exclusion Criteria:

* Unable to perform pulmonary function testing
* Clinically unstable at enrolment
* Known hypersensitivity to salbutamol
Malmö Treatment Referral and Intervention Study

This study aims to study and implement active referral of heroin users from a syringe exchange programme to evidence-based treatment for heroin addiction. Patients are randomized to either a strength-based case management intervention or a control group, while both groups receive referral to medical investigation for inclusion in substitution treatment for heroin addiction. The hypothesis is that syringe exchange can be used for referral to effective treatment, and that a strength-based intervention can increase the number of patients who are successfully referred and enter treatment.

Patients attending the syringe exchange programme of Malmö, Sweden, and who are using heroin as their primary drug of abuse and who live in the catchment area of Malmö Addiction Centre, will be addressed, and patients willing to participate will undergo a baseline interview and will be referred to medical examination for decision to start substitution treatment to treat heroin dependence. Half of patients will be randomized to a strength-based case management intervention, hypothesized to facilitate treatment entry, and half of patients will be randomized to a control condition involving only referral.

The study will measure the number of patients who successfully accept referral and initiate substitution treatment for heroin dependence, comparing patients in intervention arm to patients in the control condition (RCT design). Also, as a secondary outcome measure, retention and treatment outcome (substance use and clinical characteristics) will be compared between the two groups. In addition, this study will enable a number of sub-analyses aiming to increase knowledge about heroin addicts' detailed substance use pattern and clinical characteristics. Patients will be followed with respect to retention, substance use and clinical picture for three years.

Eligibility Criteria:
Inclusion Criteria:

* Registered at syringe exchange programme of Malmö
* Primary drug heroin
* Heroin dependence
* Living in catchment area for substitution treatment of Addiction Centre Malmö

Exclusion Criteria:

* Inability to understand consent and information
* Unstable psychiatric condition making treatment regulations impossible
* Pregnancy
Oral Glucose Tolerance Testing Using Candy for Cystic Fibrosis

The study aims to determine if a popular dextrose candy alternative yields a similar glycemic curve compared to the standard oral Dextrose solution used in the Oral Glucose Tolerance Test.


Eligibility Criteria:
Inclusion Criteria:

* Males and Females ages 10-21 years.
* Cystic Fibrosis (CF) must be diagnosed.
* Ability to sign informed consent if they are 18 years or older.
* Written parental permission if age 10-17 years old.

Exclusion criteria:

* Active CF flare as determined by the primary CF team .
* Use of steroids.
* Inability to tolerate oral feedings.
* Prior intestinal surgery.
* Concern for allergy or intolerance to dextrose, fructose, or corn derivatives.
Use of Ultrasonography for Measuring Achilles Tendon Thickness: a Novel Measurement Method

Background: Achilles tendon thickness has been associated with various diseases. Among imaging modalities, ultrasonography stands out because of its advantages in assessing Achilles tendon thickness. Previous studies typically recommend performing Achilles tendon ultrasonography with the patient in a prone position on an examination table. However, because it is not always possible or safe for each patient to assume the prone position, this study aimed to investigate the relationship between measurements obtained in the supine position and those obtained using the standard method.

Methods: A total of 180 healthy volunteers aged ≥18 years (70 female and 110 male; 360 Achilles tendons), with no history of disease or medication use, were included in the study. Achilles tendon measurements (thickness, width, and cross-sectional area) were obtained via ultrasonography in four different positions, including the standard method. The alternative methods included the supine position with the leg extended (Method 2), the supine position with the ankle resting on the opposite knee (Method 3), and the supine position with the leg held in the air at 90 degrees of hip and knee flexion (Method 4). Measurements were taken 2 cm distal from the Achilles tendon insertion on the calcaneus.


Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteers aged \>18 years who agreed to participate in the study

Exclusion Criteria:

* Individuals with tenosynovitis, tendinitis, bursitis, tuberculous arthritis, rheumatoid arthritis, a history of Achilles tendon surgery, or tendon injuries.
Study of DERMABOND ProPen in Closure of Colectomy Wounds

2-octylcyanoacrylate (2-OCA) has been used extensively in clinical practice in trauma, plastic surgery, orthopaedic surgery, emergency medicine and paediatrics. Most studies on 2-OCA to date have focused on closure of short wounds, and only one has included closure of abdominal wounds in the context of general surgery. Here, the investigators will look at the results of closure of abdominal wounds in patients undergoing elective colectomies with 2-OCA, which is commercially available to us, versus closure with skin staples, which is the current standard technique of skin closure employed in the Department of Colorectal Surgery, Singapore General Hospital. The primary objective was to measure effectiveness of 2-OCA in 2 respects - the adequacy of wound healing and cosmesis, and the incidence of superficial wound infection.


Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing elective colectomies for benign or malignant conditions
* Midline vertical incisions or skin crease incisions
* Above the age of 21 years old
* Able to make own valid informed decisions

Exclusion Criteria:

* Patients undergoing surgery for recurrent or metastatic disease
* Surgery for surgical emergencies such as acute abdomen or bleeding
* Known allergy to DERMABOND ProPen Tissue Adhesive or any of its constituents (cyanoacrylate or formaldehyde)
* Patients on immunosuppression
Proton and Carbon Ion Radiotherapy for Cervical Cancer

The aim of this study is to evaluate the toxicity and tolerance of proton and carbon ion radiotherapy (PCRT) for cervical cancer.

To retrospectively analyze cervical cancer patients received radical proton and carbon radiotherapy in our center. The acute and late toxicities, overall survival (OS), local control rate (LC), progression-free survival (PFS) and distant metastasis-free survival (DMFS) were analyzed.

Eligibility Criteria:
Inclusion Criteria:

1. . histologically diagnosis of squamous cell carcinoma of the cervix;
2. . International Federation of Gynecology and Obstetrics (FIGO) stage (2014) IB2 - IIIB, without rectum invasion; or FIGO stage IA - IB1, who refused surgery or were contraindication for surgery due to comorbidity diseases;
3. . received proton and carbon ion radiotherapy (PCRT) with or without chemotherapy for curative intention;
4. . Follow-up data available.

Exclusion Criteria:

1. a previous history of other malignancy;
2. squamous cell carcinoma of the cervix patients who had received surgery;
3. rectum was invaded.
Correlation of Disease Management and Quality of Life in Patients With Chronic Heart Failure and Their Family Caregivers

This study intends to investigate the current status of disease management and quality of life of patients with chronic heart failure and their family caregivers, explore the relationship between the two sides of disease management and quality of life, help nurses identify the influencing factors of quality of life of patients with chronic heart failure and their family caregivers, and carry out family-centered care in the future. This study intends to investigate the current status of disease management and quality of life of patients with chronic heart failure and their family caregivers, explore the relationship between disease management and quality of life of both sides, and help nurses identify the influencing factors affecting the quality of life of patients with chronic heart failure and their family caregivers, so as to carry out family-centered care in the future. To provide theoretical basis for improving the quality of life of both parties.


Eligibility Criteria:
Inclusion Criteria:

1. Meet the diagnostic criteria of Chinese Guidelines for the diagnosis and treatment of heart failure
2. the duration of chronic heart failure was ≥3 months;
3. have certain reading, comprehension and expression ability, and can complete the questionnaire independently or with the guidance of the researcher;
4. Informed and agreed to participate in the investigation

Exclusion Criteria:

* In the acute stage of the disease, such as acute heart failure attack or complicated with severe pulmonary infection, liver and kidney function damage, etc.
MOLyF : Bone Marrow and Follicular Lymphoma

This is a prospective single-center study designed to assess potential differences in cell composition between bone marrows of patients with follicular lymphoma and those from control subjects.

Follicular lymphoma is the most common indolent lymphoma. It is characterised by systematic relapses and bone marrow dissemination in 70% of patients at the time of diagnosis.

Although relapses are thought to be related to refractory tumour cells nested in a supportive microenvironment in the bone marrow, the mechanisms involved are poorly understood.

To study the specificities of the bone marrow of patients with follicular lymphoma, It is necessary to compare them with control samples.

This study takes advantage of surgeries involving sternotomies to recover lost bone marrow and establish a bone marrow bank of patients without hematological disease.

This bank will be used to set up control cohorts for other clinical trials involving patients with follicular lymphoma.


Eligibility Criteria:
Inclusion Criteria:

* Major patient
* Patient hospitalized in the thoracic, cardiac and vascular surgery department for surgery involving a sternotomy
* Patient with free, informed, written consent
* Patient covered by a health insurance scheme

Exclusion Criteria:

* History of haematological malignancy or haemogram disturbance
* Immunomodulating treatment: immunosuppressants, corticoids, antineoplastics
* Persons covered by articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code (e.g. minors, protected adults, etc.)\].